Short answer
Apogee Therapeutics, Inc. (APGE) filed its Q1 2026 10-Q quarterly report on May 11, 2026 for the quarter ended Mar 31, 2026.
Q1 2026 key financials · XBRL
- Net income
- −$74M
- −33.9% YoY
- EPS (diluted)
- −$1.06
- −11.6% YoY
Source: XBRL data from the Apogee Therapeutics, Inc. (APGE) Q1 2026 10-Q on SEC EDGAR. USD.
Apogee Therapeutics, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- Additional-capital risk: cash, cash equivalents, and marketable securities projected to fund operations through 2029 and planned zumilokibart BLA filing
- Financial-loss risk: March 31, 2026 net loss $74.1 million and accumulated deficit $635.9 million
- Regulatory risk: FDA may require additional preclinical studies or clinical trials before permitting future trial commencement
- Competitive risk: approved or emerging therapies with superior safety, efficacy, dosing, presentation, or price could reduce market opportunity
- Clinical-development risk: ongoing trials for zumilokibart, APG279, APG990, APG333, and APG808 may fail or face enrollment delays
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Apogee Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.